Connection
Daniel Pollyea to Early Termination of Clinical Trials
This is a "connection" page, showing publications Daniel Pollyea has written about Early Termination of Clinical Trials.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.047 |
|
|
|
-
Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E175-E179.
Score: 0.047